{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:28:39Z","timestamp":1787966919997,"version":"build-2784847793"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Targeted anti-HER2 therapy has been recently added to the standard treatment recommendations in endometrial serous carcinoma. Current eligibility requires testing for HER2 overexpression and\/or gene amplification by immunohistochemistry and by fluorescence in situ hybridization. However, clinical trials have also demonstrated the efficacy of anti-HER2 drugs against activating <jats:italic toggle=\"yes\">ERBB2\/HER2<\/jats:italic> mutations in a variety of solid tumor types, and fam-trastuzumab deruxtecan is now approved by the US Food and Drug Administration for <jats:italic toggle=\"yes\">HER2<\/jats:italic>-mutant non-small cell lung cancer. This study aimed at evaluating the detailed clinical, histomorphological, immunohistochemical, and molecular characteristics of gynecologic malignancies with <jats:italic toggle=\"yes\">ERBB2\/HER2<\/jats:italic> mutations. We identified 16 tumors with 19 <jats:italic toggle=\"yes\">ERBB2\/HER2<\/jats:italic> mutations in our departmental archives: 11 endometrial primaries, 2 endocervical adenocarcinomas, 1 ovarian mucinous adenocarcinoma, 1 tubo-ovarian undifferentiated carcinoma, and 1 high-grade endometrioid adenocarcinoma of Mullerian origin. <jats:italic toggle=\"yes\">ERBB2\/HER2<\/jats:italic> mutations most often involved the tyrosine kinase domain (52.6%), and the most frequent specific mutation was R678Q (31.6%), involving the juxtamembrane domain. More than half (54.5%) of endometrial carcinomas and half of all tumors were MMR-deficient, resulting from MSH6 loss in all but 2 tumors. None of the tumors (0%) were <jats:italic toggle=\"yes\">POLE-<\/jats:italic>mutated, while 18.8% were <jats:italic toggle=\"yes\">TP53<\/jats:italic>-mutated. HER2 IHC was negative (score 0 or 1+) in 12 tumors (67%) and equivocal (score 2+) in 4 tumors (33%), whereas none of the tumors were scored as HER2 3+. Score 2+ was associated with R678Q, L755S, I767M mutations, and <jats:italic toggle=\"yes\">ERBB2\/HER2<\/jats:italic> rearrangement with a breakpoint in exon 23. Concurrent <jats:italic toggle=\"yes\">ERBB2\/HER2<\/jats:italic> amplification was identified in 2 endometrial carcinomas, with HER2\/CEP17 ratios of 3.1 and 3.5. We also queried the cBioportal database, which revealed 70 <jats:italic toggle=\"yes\">ERBB2\/HER2<\/jats:italic>-mutant gynecologic tumors with a total of 77 <jats:italic toggle=\"yes\">ERBB2\/HER2<\/jats:italic> mutations, most often involving the active site of the tyrosine kinase domain (n=36; 46.8%), and the most common specific mutation was S310F (n=20; 26%), located in the extracellular domain. Our results provide important details regarding the clinicopathological and molecular associations of potentially actionable <jats:italic toggle=\"yes\">ERBB2\/HER2<\/jats:italic> mutations in endometrial carcinoma and other gynecological cancer types and contribute to addressing clinical treatment needs and improving pathology testing recommendations in the future.<\/jats:p>","DOI":"10.1097\/pgp.0000000000001050","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T22:00:50Z","timestamp":1719266450000},"page":"144-154","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Targetable ERBB2\/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations"],"prefix":"10.1097","volume":"44","author":[{"given":"Padmini A.","family":"Manrai","sequence":"first","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"McHenry","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas I.","family":"Lin","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Elvin","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"R1-20250210","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R2-20250210","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"R3-20250210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: Practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"R4-20250210","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 Testing in endometrial serous carcinoma","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"R5-20250210","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"R6-20250210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pathol.2022.11.004","article-title":"The role of HER2 as a therapeutic biomarker in gynaecological malignancy: Potential for use beyond uterine serous carcinoma","volume":"55","author":"Talia","year":"2023","journal-title":"Pathology"},{"key":"R7-20250210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: Tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod Pathol"},{"key":"R8-20250210","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","article-title":"HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology","volume":"46","author":"Jenkins","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R10-20250210","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ygyno.2020.12.021","article-title":"Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations","volume":"160","author":"Hamilton","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R11-20250210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ygyno.2020.12.024","article-title":"Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations, part II","volume":"160","author":"Hamilton","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R12-20250210","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/PAS.0000000000002030","article-title":"HER2 IHC expression and gene amplification in p53-aberrant high-grade endometrial endometrioid carcinoma suggests that this population may benefit from HER2 testing and targeted therapy","volume":"47","author":"Joehlin-Price","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"R13-20250210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/PGP.0000000000000783","article-title":"HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma","volume":"41","author":"Cagaanan","year":"2022","journal-title":"Int J Gynecol Pathol"},{"key":"R14-20250210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/cancers13010044","article-title":"HER2 status in high-risk endometrial cancers (PORTEC-3): Relationship with histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R15-20250210","doi-asserted-by":"crossref","first-page":"e1303","DOI":"10.1634\/theoncologist.2018-0845","article-title":"Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers","volume":"24","author":"Subramanian","year":"2019","journal-title":"Oncologist"},{"key":"R16-20250210","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"R17-20250210","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pharmthera.2019.03.010","article-title":"Prevalence and role of HER2 mutations in cancer","volume":"199","author":"Cocco","year":"2019","journal-title":"Pharmacol Ther"},{"key":"R18-20250210","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"R19-20250210","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","article-title":"Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations","volume":"34","author":"Pahuja","year":"2018","journal-title":"Cancer Cell"},{"key":"R20-20250210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2019.09.001","article-title":"Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 Activity","volume":"36","author":"Robichaux","year":"2019","journal-title":"Cancer Cell"},{"key":"R21-20250210","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1007\/s10238-023-01072-7","article-title":"Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: A systematic review and meta-analysis","volume":"23","author":"Zheng","year":"2023","journal-title":"Clin Exp Med"},{"key":"R22-20250210","doi-asserted-by":"crossref","first-page":"22730","DOI":"10.1073\/pnas.1911385116","article-title":"Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy","volume":"116","author":"Zammataro","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"R23-20250210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygyno.2017.12.023","article-title":"ERBB2 mutation: a promising target in non-squamous cervical cancer","volume":"148","author":"Xiang","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R24-20250210","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/s41379-020-00726-1","article-title":"Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations","volume":"34","author":"Selenica","year":"2021","journal-title":"Mod Pathol"},{"key":"R25-20250210","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.3390\/curroncol29050294","article-title":"Mutation profiles of ovarian seromucinous borderline tumors in Japanese Patients","volume":"29","author":"Sasamori","year":"2022","journal-title":"Curr Oncol"},{"key":"R26-20250210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/diagnostics10010013","article-title":"High frequency of PIK3CA mutations in low-grade serous ovarian carcinomas of Japanese Patients","volume":"10","author":"Ishibashi","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"R27-20250210","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ygyno.2021.03.019","article-title":"Mutational spectrum in clinically aggressive low-grade serous carcinoma\/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors","volume":"161","author":"Zhang","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R28-20250210","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tjog.2020.01.031","article-title":"The Her2 gene aberrations in mucinous ovarian carcinoma: Analysis of twenty-one cases","volume":"59","author":"Chiu","year":"2020","journal-title":"Taiwan J Obstet Gynecol"},{"key":"R30-20250210","first-page":"0","article-title":"Characteristics of HER2 gene amplification by fluorescence in situ hybridization in endometrial serous carcinoma","volume":"146","author":"Buza","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"R31-20250210","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized Phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"R32-20250210","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized Phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): Updated Overall Survival Analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R33-20250210","doi-asserted-by":"crossref","first-page":"1610360","DOI":"10.3389\/pore.2022.1610360","article-title":"Molecular landscape of ERBB2 alterations in 14,956 solid tumors","volume":"28","author":"Wang","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"R34-20250210","doi-asserted-by":"crossref","first-page":"103997","DOI":"10.1016\/j.critrevonc.2023.103997","article-title":"A review of HER2 overexpression and somatic mutations in cancers","volume":"186","author":"Galogre","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"R35-20250210","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1158\/1078-0432.CCR-22-0713","article-title":"Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R36-20250210","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s12282-015-0659-y","article-title":"HER2 mutation status in Japanese HER2-positive breast cancer patients","volume":"23","author":"Endo","year":"2016","journal-title":"Breast Cancer"},{"key":"R37-20250210","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/cas.13182","article-title":"HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers","volume":"108","author":"Wang","year":"2017","journal-title":"Cancer Sci"},{"key":"R38-20250210","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II Basket Trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"key":"R39-20250210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2014-0234","article-title":"Oncogenic alterations in ERBB2\/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin","volume":"20","author":"Chmielecki","year":"2015","journal-title":"Oncologist"},{"key":"R40-20250210","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cncr.31125","article-title":"Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3","volume":"124","author":"Ross","year":"2018","journal-title":"Cancer"},{"key":"R41-20250210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"R42-20250210","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.jtho.2018.07.093","article-title":"Activity of afatinib in heavily pretreated patients with ERBB2 mutation-positive advanced NSCLC: Findings From a Global Named Patient Use Program","volume":"13","author":"Peters","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R43-20250210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2020.07.025","article-title":"Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial","volume":"159","author":"Oaknin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R44-20250210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ygyno.2023.12.004","article-title":"Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial","volume":"181","author":"Friedman","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R45-20250210","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"key":"R46-20250210","doi-asserted-by":"crossref","first-page":"e2200609","DOI":"10.1200\/PO.22.00609","article-title":"Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR Study","volume":"7","author":"Ahn","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T17:02:08Z","timestamp":1739206928000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000001050","relation":{},"ISSN":["0277-1691","1538-7151"],"issn-type":[{"value":"0277-1691","type":"print"},{"value":"1538-7151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]}}}